For example, investigating liver targeting through liposomes or bile acids in liver cancer [39] could be possible future strategies to evaluate the role of RUNX1 in the pathogenesis of NAFLD. The gene discussed is RUNX1; the disease is metabolic dysfunction-associated steatotic liver disease.